Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Preferred Shares: 2014

Historic Preferred Shares for Lineage Cell Therapeutics (LCTX) over the last 1 years, with Dec 2014 value amounting to $3.5 million.

  • Lineage Cell Therapeutics' Preferred Shares changed negligibly% to $3.5 million in Q2 2015 from the same period last year, while for Jun 2015 it was $3.5 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.5 million for FY2014, which is N/A change from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Preferred Shares of $3.5 million as of FY2014.
  • Lineage Cell Therapeutics' Preferred Shares' 5-year high stood at $3.5 million during FY2014, with a 5-year trough of $3.5 million in FY2014.
  • For the 1-year period, Lineage Cell Therapeutics' Preferred Shares averaged around $3.5 million, with its median value being $3.5 million (2014).